Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review [Formula: see text].

Abstract

Pityriasis rubra pilaris (PRP) is an uncommon, inflammatory, papulosquamous skin disease. Treatment of PRP is challenging as the disease is often refractory to conventional therapies, such as retinoids and methotrexate. There has been an increasing number of studies reporting the successful use of biologic therapy in patients with PRP; however, the data on the efficacy and safety are limited. Our objective was to evaluate the existing evidence for utilizing biologics, whether alone or in combination with established systemic therapies, in patients with treatment-resistant PRP. We systematically reviewed evidence within Medline and Pubmed databases between January 1, 2000, to March 31, 2019. Articles consisted of patients diagnosed with PRP who have failed to respond sufficiently to first-line systemic therapies, or who had comorbidities that precluded their use. In total, 363 unique articles were identified, 56 of which were considered relevant to the clinical question. Of the 56 articles highlighted, 35 met the inclusion criteria and were limited to case series and case studies. Therapy with biologics was found to be successful for both monotherapy (81.1% [27/33]) and when used in combination with existing systemic therapies (87.5% [14/16]). The existing evidence suggests that biologics may be regarded as a tool for PRP treatment alone or in combination therapy with existing treatments, although large-scale randomized clinical trials are necessary to better assess their efficacy and safety.

• Authors: Avee Naidoo, Cathryn Sibbald, Patrick J Fleming, Vincent Piguet
• Journal: Journal of cutaneous medicine and surgery (J Cutan Med Surg) 2020 Jan/Feb Vol. 24 Issue 1 Pg. 73-78 ISSN: 1615-7109 [Electronic] United States
• PMID: 31691587 (Publication Type: Journal Article, Systematic Review)

Chemical References

• Biological Products
• Tumor Necrosis Factor-alpha

Topics

• Biological Products (therapeutic use)
• Humans
• Pityriasis Rubra Pilaris (drug therapy, metabolism)
• Tumor Necrosis Factor-alpha (antagonists & inhibitors)